The Competition Authority of Turkey has opened an investigation against a company nature on the suspicion that she violated the local law, and prevented competitive activity in th
Erdogan’s government news agency, Anadolu, reported that the local competition authority has completed the preliminary investigation, which dealt with the question of whether the Teva company acted to limit competition in generic drugs, including by using patent procedures for strategic purposes, and creating a “misleading” appearance before the health authorities in Ankara regarding the effectiveness and safety of certain products.
The Turkish investigation was opened against a corporation nature International, the subsidiary Teva Europe, and the subsidiary in Turkey, to determine whether they violated the law. The media, which is a direct mouthpiece of the regime, stated that Teva is a pharmaceutical company that operates all over the world, and that the investigation focuses on actions “that may act to prevent competitors from entering the market”.
The investigation currently does not lead to sanctions on Teva
As part of the investigation against the pharmaceutical company, it will be examined whether Teva’s split patent applications regarding production methods and drug dosages were received after the expiration of the patent protection period, as well as the derivative cancellation methods, which may limit similar companies. For now, the investigation does not lead to sanctions imposed on the pharmaceutical company that operates in the country.
Teva is only one Israeli company among several that still operates in Turkey. The headquarters of the pharmaceutical company in the country is located in Istanbul, and it also manages a commercial activity center for drug marketing, alongside collaborations with local organizations to improve the accessibility of medical care. The investigation against her was opened about two months after the board of the faucet company Hamat decided to close the activities of the Turkish subsidiary MCP from Izmir, due to difficulties in marketing the products in the local market and in other markets outside of Israel.
An Israeli company that is still present in the country as part of its global deployment is ICL (formerly ICL). The company operates 38 sites in 13 countries, including Great Britain, Brazil, China, Australia and also Turkey. In the company’s offices in the country, calcium phosphate and industrial cleaning agents are marketed. Despite the political tensions, a prominent player in Turkey is the Netafim irrigation company. Ownership of the company is divided between the Mexican Urbia Corporation, which owns 80% of it, and Kibbutz Hatzer, which owns 20%. The Turkish facility of the company is entrusted with the production and marketing of irrigation and agricultural support products for the local economy itself, and not for export.
Teva stated: “The investigation by the Turkish Competition Authority concerns the issue of past antitrust related to the drug Copaxone, similar to the procedure conducted by the European Commission, which is currently under appeal before the European Court of Justice, in which Teva rejects any allegation of wrongdoing on its part. This is an investigative procedure, and we will cooperate with the authorities throughout the process.”
For your attention: The Globes system strives for a diverse, relevant and respectful discourse in accordance with the code of ethics that appears in the trust report according to which we operate. Expressions of violence, racism, incitement or any other inappropriate discourse are filtered out automatically and will not be published on the site.